Stay updated with breaking news from Actrims. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccinationData from this analysis also suggest
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 One-year results from Phase 2b extension study of brain-penetrant tolebrutinib
![New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated [...] - Vimarsana News](https://www.cataniaoggi.it/img/logo_social.jpg){kind=logo}
25 febbraio 2021 14:05 Fonte: Adnkronos #chimica-e-farmacia MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial findings from the CLOCK-MS vaccine sub-study show protective influenza antibody levels at four weeks post-vaccination in MS patients taking MAVENCLAD In both studies, protective antibody levels were maintained or increased independent of lymphocyte counts DARMSTADT, Germany, Feb. 25, 2021 /PRNew...